MX2022010512A - Inhibidores de proteína bcl-2. - Google Patents
Inhibidores de proteína bcl-2.Info
- Publication number
- MX2022010512A MX2022010512A MX2022010512A MX2022010512A MX2022010512A MX 2022010512 A MX2022010512 A MX 2022010512A MX 2022010512 A MX2022010512 A MX 2022010512A MX 2022010512 A MX2022010512 A MX 2022010512A MX 2022010512 A MX2022010512 A MX 2022010512A
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- protein inhibitors
- formula
- various
- tumors
- Prior art date
Links
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 title abstract 3
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 title abstract 3
- 229940121649 protein inhibitor Drugs 0.000 title abstract 3
- 239000012268 protein inhibitor Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen varios inhibidores de la proteína Bcl-2, junto con métodos para usarlos para tratar afecciones caracterizadas por una proliferación celular excesiva, tales como cáncer y tumores. En varias modalidades, los inhibidores de la proteína Bcl-2 son compuestos o sales farmacéuticamente aceptables de la siguiente Fórmula (I), donde las variables en la Fórmula (I) se definen en la presente descripción. (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016760P | 2020-04-28 | 2020-04-28 | |
| PCT/US2021/029181 WO2021222114A1 (en) | 2020-04-28 | 2021-04-26 | Bcl-2 protein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010512A true MX2022010512A (es) | 2022-11-16 |
Family
ID=78332399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010512A MX2022010512A (es) | 2020-04-28 | 2021-04-26 | Inhibidores de proteína bcl-2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230167105A1 (es) |
| EP (1) | EP4107152A4 (es) |
| JP (1) | JP2023524439A (es) |
| KR (1) | KR20230002483A (es) |
| CN (1) | CN115461335A (es) |
| AU (1) | AU2021263568A1 (es) |
| BR (1) | BR112022021910A2 (es) |
| CA (1) | CA3173843A1 (es) |
| IL (1) | IL297586A (es) |
| MX (1) | MX2022010512A (es) |
| TW (1) | TW202206424A (es) |
| WO (1) | WO2021222114A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021007307A1 (en) * | 2019-07-10 | 2021-01-14 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| US20250282771A1 (en) | 2022-05-06 | 2025-09-11 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| PE20250007A1 (es) | 2022-05-06 | 2025-01-07 | Treeline Biosciences Inc | Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina |
| JP2025516359A (ja) | 2022-05-06 | 2025-05-27 | ツリーライン バイオサイエンシズ インコーポレイテッド | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 |
| WO2024078581A1 (en) * | 2022-10-12 | 2024-04-18 | Appicine Therapeutics (Hk) Limited | Selective bcl-xl protac compounds and uses thereof |
| WO2024179577A1 (zh) * | 2023-03-01 | 2024-09-06 | 西藏海思科制药有限公司 | 一种Bcl-2家族蛋白降解剂的药物组合物 |
| WO2025101575A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| TW202527930A (zh) | 2023-11-07 | 2025-07-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| WO2025101571A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6936498B2 (ja) * | 2016-04-21 | 2021-09-15 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
| EP3737681A4 (en) * | 2018-01-10 | 2022-01-12 | Recurium IP Holdings, LLC | BENZAMIDE COMPOUNDS |
| EP3743069B1 (en) * | 2018-01-22 | 2025-08-06 | BioVentures, LLC | Bcl-2 proteins degraders for cancer treatment |
| WO2021007307A1 (en) * | 2019-07-10 | 2021-01-14 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
-
2021
- 2021-04-26 MX MX2022010512A patent/MX2022010512A/es unknown
- 2021-04-26 EP EP21796922.9A patent/EP4107152A4/en not_active Withdrawn
- 2021-04-26 US US17/997,335 patent/US20230167105A1/en active Pending
- 2021-04-26 CA CA3173843A patent/CA3173843A1/en active Pending
- 2021-04-26 WO PCT/US2021/029181 patent/WO2021222114A1/en not_active Ceased
- 2021-04-26 KR KR1020227037005A patent/KR20230002483A/ko not_active Withdrawn
- 2021-04-26 CN CN202180031652.XA patent/CN115461335A/zh active Pending
- 2021-04-26 IL IL297586A patent/IL297586A/en unknown
- 2021-04-26 BR BR112022021910A patent/BR112022021910A2/pt not_active Application Discontinuation
- 2021-04-26 AU AU2021263568A patent/AU2021263568A1/en not_active Abandoned
- 2021-04-26 JP JP2022565793A patent/JP2023524439A/ja active Pending
- 2021-04-28 TW TW110115357A patent/TW202206424A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021222114A1 (en) | 2021-11-04 |
| CA3173843A1 (en) | 2021-11-04 |
| US20230167105A1 (en) | 2023-06-01 |
| CN115461335A (zh) | 2022-12-09 |
| KR20230002483A (ko) | 2023-01-05 |
| AU2021263568A1 (en) | 2022-09-22 |
| JP2023524439A (ja) | 2023-06-12 |
| EP4107152A4 (en) | 2023-07-26 |
| EP4107152A1 (en) | 2022-12-28 |
| BR112022021910A2 (pt) | 2022-12-13 |
| TW202206424A (zh) | 2022-02-16 |
| IL297586A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010512A (es) | Inhibidores de proteína bcl-2. | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| MX2024000357A (es) | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). | |
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| MX2024004444A (es) | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). | |
| MX2023009185A (es) | Compuestos de benzamida. | |
| MX2025003821A (es) | Compuestos con actividad contra tumores mutantes de kras | |
| PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MX2023004802A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
| GEAP202215630A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| MX2024013215A (es) | Compuestos para inhibir kif18a | |
| MX2023004373A (es) | Metodos y composiciones para la degradacion dirigida de proteinas. | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| WO2020210320A8 (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| WO2024006292A3 (en) | Methods of treating cancer | |
| PH12022550078A1 (en) | Enzyme inhibitors | |
| MX2024013787A (es) | Inhibidores de menina-mll para el tratamiento de cáncer. | |
| WO2024163641A3 (en) | Formulations for treating cancer | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 |